NHI.no
Annonse
Informasjon

Guillain-Barré syndrom

Guillain-Barré er et syndrom med akutt innsettende svakhet og smerter i beina. Det oppstår lammelser som brer seg oppover og som i cirka 25 prosent av tilfellene også svekker pustemusklene.

Guillain-Barré syndrom starter ofte etter en forutgående infeksjon. To til fire uker senere begynner det å prikke og brenne i føtter og eventuelt hender.

Sist oppdatert:

11. okt. 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Guillain-Barré syndrom . Referanselisten for dette dokumentet vises nedenfor

  1. Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician 2013; 87: 191-7. American Family Physician
  2. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology 2019; 15: 671–683 .
  3. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Seminar. Lancet 2021; 397: 1214-28. doi:10.1016/S0140-6736(21)00517-1 DOI
  4. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123-33. PubMed
  5. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. Epub 2016 Mar 2. pmid: 2694843 PubMed
  6. Leonhard SE, van der Eijk AA, Andersen H, et al. An International Perspective on Preceding Infections in Guillain-Barré Syndrome The IGOS-1000 Cohort. Neurology 2022. pmid:35981895 PubMed
  7. Bishara H, Arbel A, Barnett-Griness O, et al. Association between Guillain-Barré syndrome and COVID-19 infection and vaccination: A population-based nested case-control study. Neurology 2023; 101:e2035. PMID: 37852786 PubMed
  8. Le Vu S, Bertrand M, Botton J, et al. Risk of Guillain-Barré syndrome following COVID-19 vaccines: A nationwide self-controlled case series study. Neurology 2023; 101: e2094-e2102. PMID: 37788935 PubMed
  9. Rocha Cabrero F, Morrison EH. Miller Fisher syndrome. 2021. In StatPearls. Treasure Island, FL StatPearls Publishing 2021. www.ncbi.nlm.nih.gov
  10. Hughes RAC, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130: 2245-57. PubMed
  11. Rudolph T, Larsen JP, Farbu E. The long-term functional status in patients with Guillain-Barré syndrome. Eur J Neurol. 2008 Dec. 15(12):1332-7.
  12. Cohen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM-sleep in Guillain-Barré syndrome. Brain 2005; 128: 2535-45. PubMed
  13. Nobuhiro Y, Hartung H-P. Guillain-Barré syndrome. N Engl J Med 2012; 366: 2294-304. New England Journal of Medicine
  14. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58: 913-7. PubMed
  15. Winer JB. Guillain-Barre syndrom. Clinical review. BMJ 2008; 337: a671. PubMed
  16. Gorson KC, Ropper AH, Muriello MA, et al. Prospective evaluation of MRI lumbosacral root enhancement in acute Guillain–Barré syndrome. Neurology 1996; 47: 813–17.
  17. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-40. Neurology
  18. Vriesendorp FJ. Guillain-Barré syndrome in adults: Clinical features and diagnosis. UpToDate, last updated Dec 04, 2018. UpToDate
  19. Gerdts R, Jensen D, Fauchald P, Skjeldal O, Guillain-Barré Syndrome. Moderne behandlingsprinsipper belyst ved et klinisk materiale, Tidsskr Nor lægeforen 1999; 119: 506-9
  20. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD002063. DOI: 10.1002/14651858.CD002063.pub6. DOI
  21. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD001798. DOI: 10.1002/14651858.CD001798.pub2. DOI
  22. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446 . pmid:27775812 PubMed
  23. van Koningsveld R, Schmitz PIM, van der Meché FGA, et al. Effect of methylprednisolone when added to standard treatement with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363: 192-6. PubMed
  24. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain 1996; 119(pt 6): 2053-61.
  25. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 1996; 74: 281. PubMed
  26. NevroNEL. Guillain-Barré syndrom. Norsk Nevrologisk Forening. Sist oppdatert sept. 2020. Siden lest 07.04.2021 nevrologi.legehandboka.no
  27. Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome. Neurology 1999; 52: 635-8. Neurology
  28. Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. 2010 Dec. 257(12):2024-31.
  29. Das A, Kalita J, Misra UK. Recurrent Guillain Barre' syndrome. Electromyogr Clin Neurophysiol. 2004 Mar. 44(2):95-102.
Annonse
Annonse